Publications by authors named "Tim Akhurst"

Claim this Profile
P
Prognostic Value of Initial Imaging and PSA Change with [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
David C Chen, James P Buteau, Nathan Papa, Tim Akhurst, Ramin Alipour

J Nucl Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177 [Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Louise Kostos, James P Buteau, Jing Xie, Anthony Cardin, Tim Akhurst

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of re-treatment with [Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.
Raghava Kashyap, Ramin Alipour, Emma Boehm, Kerry Jewell, Aravind S RaviKumar, Tim Akhurst

Eur J Nucl Med Mol Imaging· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human results of terbium-161 [Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
James P Buteau, Louise Kostos, Price A Jackson, Jing Xie, Mohammad B Haskali, Tim Akhurst

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Response Relationships Between Radiation Exposure, Bone Marrow Function as Measured by F-Fluorothymidine Positron Emission Tomography, and Lymphocyte Counts During Chemoradiation for Non-Small Cell Lung Cancer.
Michael P MacManus, Elizabeth Prins, Jing Xie, Tim Akhurst, Rodney J Hicks

Int J Radiat Oncol Biol Phys· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin.
Anna Ugalde, Richard W Tothill, Stephen Quinn, Hui-Li Wong, Owen Prall, Tim Akhurst

BMC Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to COVID-19 vaccination imaged by PD-L1 PET scanning.
Michael P MacManus, Tim Akhurst, Sharon R Lewin, Fiona Hegi-Johnson

EJNMMI Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang

Endocr Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
Fiona Hegi-Johnson, Stacey E Rudd, Christian W Wichmann, Tim Akhurst, Peter Roselt

Int J Radiat Oncol Biol Phys· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
Nathaniel Barry, Roslyn J Francis, Martin A Ebert, Eng-Siew Koh, Pejman Rowshanfarzad, Tim Akhurst

Eur J Nucl Med Mol Imaging· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt

BMJ Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases.
Tim Akhurst, Mithat Gönen, Raymond E Baser, Lawrence H Schwartz, Scott Tuorto

Hepatobiliary Surg Nutr· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei.
Michael P Flood, Joseph C Kong, Toan Pham, Peadar S Waters, Mikael Soucisse, Tim Akhurst

Eur J Surg Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans.
Bradley J Beattie, Tim J Akhurst, Finn Augensen, John L Humm

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J Gross, Tim Akhurst

J Nucl Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN.
Imogen Caldwell, David Byrne, Stephen Lade, Tim Akhurst, Adrian Minson

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nodal metabolic tumour volume on baseline F-FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy.
Ramin Alipour, Nick Bucknell, Mathias Bressel, Sarah Everitt, Michael MacManus, Tim Akhurst

J Med Imaging Radiat Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series.
Amir Iravani, Catherine Mitchell, Tim Akhurst, Shahneen Sandhu, Michael S Hofman

Clin Genitourin Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on Ga-DOTATATE PET/CT and F-FDG PET/CT.
Lamiaa Zidan, Amir Iravani, Grace Kong, Tim Akhurst, Michael Michael

Eur J Nucl Med Mol Imaging· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Amir Iravani, Medhat M Osman, Alison M Weppler, Roslyn Wallace, Anna Galligan, Tim Akhurst

Eur J Nucl Med Mol Imaging· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Tim Akhurst

Eur J Nucl Med Mol Imaging· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue-Ping Thang, Tim Akhurst

J Nucl Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).
Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst

Contemp Clin Trials Commun· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy.
Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst

Eur Urol Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Amir Iravani, Benjamin Solomon, David A Pattison, Price Jackson, Aravind Ravi Kumar, Tim Akhurst

Thyroid· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis